Table 2.

Summary statistics for PB plasma log10-transformed, glucose-corrected ox-mtDNA in patients and healthy controls

nMeanMedianSDP compared with
NormalLR MDSHR MDSMDS
Healthy 29 1.5765 1.585941 0.15 NA 6.9 × 10–44 1.1 × 10–7 1.23 × 10–42 
LR MDS 162 2.557 2.481877 0.38 6.86 × 10–44 NA 2.1 × 10–4 NA 
HR MDS 14 2.2089 2.20 0.27 1.1 × 10–7 2.1 × 10–4 NA NA 
MDS 176 2.5275 2.452618 0.38 1.2 × 10–42 NA NA NA 
ALL* 6 1.8149 1.862336 0.41 4.4 × 10–2 1.8 × 10–4 3.6 × 10–2 2.7 × 10–4 
Anemia* 6 1.9285 1.88186592 0.18 7.0 × 10–4 2.2 × 10–4 3.7 × 10–2 3.3 × 10–4 
CHIP 25 2.0085 2.0347573 0.18 2.5 × 10–12 2.4 × 10–17 2.0 × 10–2 2.5 × 10–16 
CLL 45 2.5463 2.527587 0.27 1.2 × 10–30 8.3 × 10–1 3.6 × 10–4 7.0 × 10–1 
CML* 9 1.958 1.984861 0.31 9.2 × 10–4 6.0 × 10–5 6.0 × 10–2 1.0 × 10–4 
CMML 16 2.2366 2.179886 0.29 4.9 × 10–8 5.3 × 10–4 7.9 × 10–1 1.3 × 10–3 
De novo AML 12 1.8792 1.770521 0.26 2.3 × 10–3 6.9 × 10–7 4.1 × 10–3 1.3 × 10–6 
ET 18 1.9892 1.975373 0.16 2.1 × 10–10 2.8 × 10–15 1.2 × 10–2 2.0 × 10–14 
LGL 17 2.1418 2.161461 0.28 1.5 × 10–7 1.3 × 10–5 5.0 × 10–1 3.3 × 10–5 
MF 11 1.785 1.570546 0.44 1.5 × 10–1 1.4 × 10–4 1.3 × 10–2 2.0 × 10–4 
Myeloma 18 1.9017 1.943949 0.11 1.1 × 10–10 1.1 × 10–26 7.2 × 10–4 1.9 × 10–25 
PV 18 1.9292 1.967492 0.18 8.9 × 10–8 2.3 × 10–14 2.5 × 10–3 1.2 × 10–13 
Secondary AML 26 1.984 1.973814 0.24 4.1 × 10–9 1.1 × 10–13 1.4 × 10–2 6.5 × 10–13 
T2D 25 1.7453 1.80 0.20 1.4 × 10–3 2.9 ×10–22 8.2 × 10–6 2.3 × 10–21 
Normal discovery 29 1.5765 1.58 0.15 6.1 × 10–1† 
Normal validation 30 1.5558 1.53 0.15 
MDS discovery 176 2.5275 2.45 0.38 8.4 × 10–10† 
MDS validation 113 2.2133 2.13 0.47 
nMeanMedianSDP compared with
NormalLR MDSHR MDSMDS
Healthy 29 1.5765 1.585941 0.15 NA 6.9 × 10–44 1.1 × 10–7 1.23 × 10–42 
LR MDS 162 2.557 2.481877 0.38 6.86 × 10–44 NA 2.1 × 10–4 NA 
HR MDS 14 2.2089 2.20 0.27 1.1 × 10–7 2.1 × 10–4 NA NA 
MDS 176 2.5275 2.452618 0.38 1.2 × 10–42 NA NA NA 
ALL* 6 1.8149 1.862336 0.41 4.4 × 10–2 1.8 × 10–4 3.6 × 10–2 2.7 × 10–4 
Anemia* 6 1.9285 1.88186592 0.18 7.0 × 10–4 2.2 × 10–4 3.7 × 10–2 3.3 × 10–4 
CHIP 25 2.0085 2.0347573 0.18 2.5 × 10–12 2.4 × 10–17 2.0 × 10–2 2.5 × 10–16 
CLL 45 2.5463 2.527587 0.27 1.2 × 10–30 8.3 × 10–1 3.6 × 10–4 7.0 × 10–1 
CML* 9 1.958 1.984861 0.31 9.2 × 10–4 6.0 × 10–5 6.0 × 10–2 1.0 × 10–4 
CMML 16 2.2366 2.179886 0.29 4.9 × 10–8 5.3 × 10–4 7.9 × 10–1 1.3 × 10–3 
De novo AML 12 1.8792 1.770521 0.26 2.3 × 10–3 6.9 × 10–7 4.1 × 10–3 1.3 × 10–6 
ET 18 1.9892 1.975373 0.16 2.1 × 10–10 2.8 × 10–15 1.2 × 10–2 2.0 × 10–14 
LGL 17 2.1418 2.161461 0.28 1.5 × 10–7 1.3 × 10–5 5.0 × 10–1 3.3 × 10–5 
MF 11 1.785 1.570546 0.44 1.5 × 10–1 1.4 × 10–4 1.3 × 10–2 2.0 × 10–4 
Myeloma 18 1.9017 1.943949 0.11 1.1 × 10–10 1.1 × 10–26 7.2 × 10–4 1.9 × 10–25 
PV 18 1.9292 1.967492 0.18 8.9 × 10–8 2.3 × 10–14 2.5 × 10–3 1.2 × 10–13 
Secondary AML 26 1.984 1.973814 0.24 4.1 × 10–9 1.1 × 10–13 1.4 × 10–2 6.5 × 10–13 
T2D 25 1.7453 1.80 0.20 1.4 × 10–3 2.9 ×10–22 8.2 × 10–6 2.3 × 10–21 
Normal discovery 29 1.5765 1.58 0.15 6.1 × 10–1† 
Normal validation 30 1.5558 1.53 0.15 
MDS discovery 176 2.5275 2.45 0.38 8.4 × 10–10† 
MDS validation 113 2.2133 2.13 0.47 

ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CHIP, clonal hematopoiesis of indeterminate potential; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; ET, essential thrombocytosis; LGL, large granular lymphocytic leukemia; MF, myelofibrosis; NA, not available; PV, polycythemia vera; T2D, type 2 diabetes.

*

P values represent Kruskal-Wallis significance values because of low numbers of patients.

†

P values compare discovery to validation patients and discovery normal controls to validation controls.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal